Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines

[1]  S. Tsao,et al.  Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines , 2013, Investigational New Drugs.

[2]  W. Liao,et al.  The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  J. Minna,et al.  STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. , 2011, Cancer research.

[4]  H. Hong,et al.  Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. , 2011, Biochemical and biophysical research communications.

[5]  Kang-Yell Choi,et al.  MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. , 2011, Cancer research.

[6]  A. Iafrate,et al.  BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation , 2010, Science Signaling.

[7]  W. Sellers,et al.  PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. , 2010, Cancer research.

[8]  S. Tsao,et al.  Abstract 1638: Preclinical evaluation of the PI3K inhibitor BEZ235 in nasopharyngeal carcinoma cell lines , 2010 .

[9]  S. Cook,et al.  Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines , 2009, International journal of cancer.

[10]  Y. Bang,et al.  Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells , 2009, Molecular Cancer Therapeutics.

[11]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[12]  T. Mok,et al.  A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy , 2008, Cancer Chemotherapy and Pharmacology.

[13]  Mhairi A. Morris,et al.  Epstein-Barr Virus-Encoded LMP1 Regulates Epithelial Cell Motility and Invasion via the ERK-MAPK Pathway , 2008, Journal of Virology.

[14]  M. Herlyn,et al.  The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel , 2008, Clinical Cancer Research.

[15]  Gen Sheng Wu,et al.  ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. , 2007, Cancer research.

[16]  H. Huynh,et al.  AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma , 2007, Molecular Cancer Therapeutics.

[17]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[18]  N. Raab-Traub,et al.  Unique Signaling Properties of CTAR1 in LMP1-Mediated Transformation , 2007, Journal of Virology.

[19]  M. Osmak,et al.  Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. , 2007, Cancer letters.

[20]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[21]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[22]  Y. Lau,et al.  Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. , 2006, Neoplasia.

[23]  A. Hui,et al.  PIK3CA mutations in nasopharyngeal carcinoma , 2006, International journal of cancer.

[24]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[25]  M. Beeram,et al.  Raf: a strategic target for therapeutic development against cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Beeram,et al.  Regulation of c-Raf-1: therapeutic implications. , 2003, Clinical advances in hematology & oncology : H&O.

[27]  Y. Wong,et al.  Alterations of Biologic Properties and Gene Expression in Nasopharyngeal Epithelial Cells by the Epstein-Barr Virus–Encoded Latent Membrane Protein 1 , 2003, Laboratory Investigation.

[28]  S. Tsao,et al.  The significance of LMP1 expression in nasopharyngeal carcinoma. , 2002, Seminars in cancer biology.

[29]  A. Hui,et al.  Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. , 2002, International journal of oncology.

[30]  N. Cooper,et al.  Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. , 1998, Virology.

[31]  Q. Tao,et al.  Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response , 2010, Investigational new drugs.

[32]  C. Tzen,et al.  PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival , 2009, Medical oncology.

[33]  S. Thibodeau,et al.  Signal-Regulated Kinase and Raf Proteins Negative Feedback Pathways between Extracellular BRAF V 600 E Disrupts AZD 6244-Induced Abrogation of Updated , 2008 .

[34]  T. Poon,et al.  Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. , 2005, In vivo.